Oxford Finance LLC
Oxford Finance delivers flexible financial solutions to healthcare and life sciences companies worldwide.
Business Model:
Revenue: $25M
Employees: 51-200
Rankings
Industries / Tags:
Detailed Oxford Finance LLC Information
Geographic Data
Address: 115 South Union Street
City: Alexandria
State: VA
Zip: 22314
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$900M
Social
Linkedin
Crunchbase
Metrics
2,110,333Website Global Rank
9,425Website Monthly Traffic
Twitter Followers
Description
Oxford Finance LLC delivers flexible financial solutions to healthcare and life sciences companies worldwide. Our capital provides clients with the fuel needed for innovation and growth.
Contact Phone:
+17035194900
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 10/2019 | LogicBio Therapeutics | Post-IPO Debt | 20M |
| 9/2012 | CareDx | Debt Financing | 15M |
| 5/2022 | Silk Road Medical | Post-IPO Debt | 250M |
| 4/2019 | Summit Healthcare REIT | Debt Financing | 96M |
| 1/2017 | Oxford BioTherapeutics | Debt Financing | 10M |
| 8/2016 | Bi02 Medical | Debt Financing | 3M |
| 8/2014 | HTG Molecular Diagnostics | Debt Financing | 16M |
| 2/2012 | Ceptaris Therapeutics | Debt Financing | 15M |
| 1/2015 | InterValve | Debt Financing | 3M |
| 12/2016 | Strongbridge Biopharma | Post-IPO Debt | 40M |
| 8/2011 | Keystone Dental | Debt Financing | 20M |
| 8/2019 | ObsEva | Post-IPO Debt | 75M |
| 1/2016 | Omeros | Post-IPO Debt | 70M |
| 6/2014 | Intellicyt | Debt Financing | 4M |
| 5/2016 | Omeros | Post-IPO Debt | 20M |
| 3/2014 | Omeros | Post-IPO Debt | 32M |
| 11/2022 | Renibus Therapeutics | Debt Financing | 10M |
| 4/2015 | Inhibrx | Debt Financing | 20M |
| 9/2007 | CASI Pharmaceuticals | Post-IPO Debt | 20M |
| 11/2015 | Venus Concept | Debt Financing | 20M |
| 6/2016 | Monteris Medical | Debt Financing | 10M |
| 5/2015 | Labcyte | Debt Financing | 17M |
| 12/2016 | Veran Medical Technologies | Venture Round | 31M |
| 1/2021 | Immunocore | Debt Financing | 100M |
| 6/2014 | Durect | Post-IPO Equity | 20M |
| 2/2020 | Genapsys | Debt Financing | 75M |
| 7/2013 | Continuum Healthcare | Debt Financing | 11.5M |
| 4/2012 | NanoString Technologies | Debt Financing | 15M |
| 7/2012 | LENSAR, Inc. | Debt Financing | 10M |
| 1/2016 | Bi02 Medical | Debt Financing | 5M |
| 4/2021 | Mainstay Medical | Debt | 50M |
| 11/2018 | Nevakar | Debt Financing | 30M |
| 4/2014 | Senseonics | Debt Financing | 10M |
| 4/2018 | Cardiac Dimensions | Series B | 39M |
| 12/2013 | Halozyme Therapeutics | Post-IPO Debt | 30M |
| 1/2014 | Halozyme Therapeutics | Post-IPO Debt | 20M |
| 11/2021 | Kezar Life Sciences | Post-IPO Debt | 50M |
| 12/2020 | Greenbrook TMS | Post-IPO Debt | 30M |
| 3/2011 | SynergEyes | Venture Round | 5M |
| 11/2007 | BioVex | Series E | 35M |
| 2/2009 | Pearl Therapeutics | Debt Financing | 8M |
| 6/2022 | SeLux Diagnostics | Debt Financing | 0 |
| 6/2014 | Relypsa | Post-IPO Debt | 35M |
| 7/2010 | Zogenix | Venture Round | 0 |
| 12/2013 | Acura Pharmaceuticals | Post-IPO Debt | 10M |
| 12/2015 | MDRejuvena | Debt Financing | 3M |
| 11/2011 | Avantis Medical Systems | Debt Financing | 3M |
| 1/2022 | Sierra Oncology | Post-IPO Debt | 125M |
| 6/2016 | Ignyta | Post-IPO Debt | 42M |
| 10/2020 | Scholar Rock | Post-IPO Debt | 50M |
| 5/2019 | RefleXion Medical | Debt Financing | 60M |
| 11/2014 | Lexicon Pharmaceuticals | Equity | 150M |
| 7/2018 | QuVa Pharma | Debt Financing | 41M |
| 11/2018 | Karius | Debt Financing | 25M |
| 4/2016 | Nuvectra | Debt Financing | 45M |
| 3/2014 | Navidea Biopharmaceuticals | Post-IPO Debt | 30M |
| 1/2019 | AliveCor | Debt Financing | 20M |
| 1/2013 | Agile Therapeutics | Debt Financing | 15M |
| 7/2013 | Plus Therapeutics | Post-IPO Debt | 27M |
| 1/2014 | Proteus Digital Health | Debt Financing | 31.6M |
| 4/2015 | ReShape Lifesciences | Post-IPO Debt | 12M |
| 4/2014 | RF Surgical Systems | Venture Round | 15M |
| 9/2014 | Asensus Surgical | Post-IPO Debt | 25M |
| 8/2015 | Ocera Therapeutics | Post-IPO Debt | 20M |
| 7/2014 | Cerus | Post-IPO Debt | 30M |
| 12/2020 | RxSight | Debt Financing | 60M |
| 3/2011 | NeoVista | Debt Financing | 20M |
| 10/2013 | Monteris Medical | Debt Financing | 5M |
| 11/2015 | Continuum Healthcare | Debt Financing | 13.9M |
| 10/2019 | Equillium | Post-IPO Debt | 20M |
| 10/2022 | ALX Oncology | Post-IPO Debt | 100M |
| 9/2020 | Vedanta Biosciences | Debt Financing | 15M |
| 10/2012 | Entellus Medical | Debt Financing | 17M |
| 9/2020 | Selecta Biosciences | Post-IPO Debt | 35M |
| 7/2015 | AlterG | Debt Financing | 15M |
| 7/2010 | Tethys BioScience | Debt Financing | 10M |
| 11/2015 | Zyga Technology | Debt Financing | 15M |
| 6/2012 | Avanir Pharmaceuticals | Post-IPO Debt | 30M |
| 10/2013 | Monteris Medical | Venture Round | 0 |
| 6/2016 | Regulus Therapeutics | Post-IPO Debt | 30M |
| 6/2022 | Antheia | Debt Financing | 0 |
| 12/2013 | Apollo Endosurgery | Debt Financing | 50M |
| 8/2014 | diaDexus | Post-IPO Debt | 15M |
| 11/2022 | Pearl Street | Debt Financing | 115M |
| 8/2013 | PrimeSource Healthcare Systems | Debt Financing | 5.5M |
| 1/2017 | Eiger BioPharmaceuticals | Post-IPO Debt | 25M |
| 3/2019 | Evolus | Post-IPO Debt | 100M |
| 7/2021 | 4D Pharma | Post-IPO Debt | 29.9M |
| 2/2019 | Continuing Healthcare Solutions | Debt Financing | 43.3M |
| 4/2017 | Cerapedics | Debt Financing | 20M |
| 6/2019 | AcelRx Pharmaceuticals | Post-IPO Debt | 25M |
| 5/2017 | Castle Biosciences | Debt Financing | 20M |
| 12/2013 | Amicus Therapeutics | Post-IPO Debt | 10M |
| 4/2014 | Larimar Therapeutics | Debt Financing | 20M |
| 2/2020 | Syros Pharmaceuticals | Debt Financing | 60M |
| 3/2016 | Superior Biologics | Debt Financing | 50M |
| 7/2010 | Zogenix | Debt Financing | 35M |
| 12/2020 | Nature’s Fynd | Debt Financing | 45M |
| 1/2015 | Minerva Neuroscience | Post-IPO Debt | 15M |
| 1/2022 | Choice Health at Home | Debt Financing | 0 |
| 5/2013 | CardioFocus | Debt Financing | 11M |
| 11/2017 | Puma Biotechnology | Post-IPO Equity | 100M |
| 5/2016 | ADMA Biologics | Post-IPO Debt | 4M |
| 8/2017 | AirXpanders | Post-IPO Debt | 15M |
| 10/2020 | SpendMend | Debt Financing | 55M |
| 6/2015 | ADMA Biologics | Post-IPO Debt | 21M |
| 9/2013 | Singulex, Inc. | Debt Financing | 40M |
| 9/2019 | Codex DNA | Series A | 25M |
| 7/2016 | Senseonics | Post-IPO Debt | 30M |
| 11/2017 | VitalConnect | Debt Financing | 20M |
| 2/2012 | Horizon Pharma | Post-IPO Debt | 60M |
| 4/2015 | Celula | Debt Financing | 10M |
| 4/2007 | Argos Therapeutics | Debt Financing | 5M |
| 2/2022 | Centogene | Post-IPO Debt | 0 |
| 3/2020 | Epic Healthcare Staffing | Debt Financing | 104.3M |
| 1/2017 | ConforMIS | Post-IPO Debt | 50M |
| 2/2011 | Intuity Medical | Venture Round | 20M |
| 7/2021 | Impel NeuroPharma | Debt Financing | 50M |
| 11/2021 | Viracta Therapeutics | Post-IPO Debt | 0 |
| 9/2020 | Enable Injections | Debt Financing | 25M |
| 4/2014 | Conventus Orthopaedics | Debt Financing | 10M |
| 6/2014 | Tobira Therapeutics | Debt Financing | 15M |
| 8/2019 | MolecuLight | Debt Financing | 7.5M |
| 4/2017 | Reata Pharmaceuticals | Post-IPO Debt | 35M |
| 9/2010 | SuperDimension | Debt | 15M |
| 5/2021 | Kala Pharmaceuticals | Post-IPO Debt | 125M |
| 12/2013 | CymaBay Therapeutics | Debt Financing | 5M |
| 3/2022 | Verastem Oncology | Post-IPO Debt | 0 |
| 10/2022 | Verona Pharma | Post-IPO Debt | 150M |
| 3/2011 | AirXpanders | Series C | 3M |
| 3/2018 | Xeris Pharmaceuticals | Debt Financing | 45M |
| 5/2012 | Pacira Pharmaceuticals | Post-IPO Debt | 27.5M |
| 7/2014 | Cardiff Oncology | Post-IPO Debt | 15M |
| 10/2007 | Tengion | Series C | 33M |
| 11/2021 | Platelet BioGenesis | Series B | 75.5M |
| 1/2014 | Auspex Pharmaceuticals | Debt Financing | 15M |
| 10/2009 | Zogenix | Series B | 36M |
| 8/2016 | CVRx | Debt Financing | 20M |
| 9/2014 | Trevena | Post-IPO Debt | 35M |
| 12/2015 | Aratana Therapeutics | Post-IPO Debt | 40M |
| 8/2014 | Tarsa Therapeutics | Debt Financing | 10M |
| 9/2014 | Pulmonx | Debt Financing | 20M |
| 5/2014 | Ceterix Orthopaedics | Debt Financing | - |
| 5/2015 | Edgemont Pharmaceuticals | Debt Financing | 5M |
| 9/2020 | Collage Rehabilitation Partners | Debt Financing | - |
| 9/2019 | Xeris Pharmaceuticals | Post-IPO Debt | 85M |
| 6/2022 | Antheia | Debt Financing | 0 |
| 6/2022 | SeLux Diagnostics | Debt Financing | 0 |
| 5/2022 | Silk Road Medical | Post-IPO Debt | 0 |
| 3/2022 | Verastem Oncology | Post-IPO Debt | 0 |
| 3/2022 | Lexicon Pharmaceuticals | Post-IPO Debt | 0 |
| 2/2022 | Centogene | Post-IPO Debt | 0 |
| 1/2022 | Sierra Oncology | Post-IPO Debt | 0 |
| 1/2022 | Choice Health at Home | Debt Financing | 0 |
| 11/2021 | Kezar Life Sciences | Post-IPO Debt | 0 |
| 11/2021 | Viracta Therapeutics | Post-IPO Debt | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
